GlaxoSmithKline has hailed a major step forward for an ovarian cancer drug it acquired last year, announcing that it has been effective in stopping the spread of ovarian cancer.
The announcement is a significant boost for the drugs giant, which has come under pressure from investors who are concerned that it is failing to keep pace with some of its industry peers.
GSK said Zejula demonstrated its effectiveness in stopping the spread of the cancer when taken as the first treatment after a patient has undergone chemotherapy.
It gained Zejula in December as part of its controversial 5.1 billion US dollar (£4 billion) acquisition of oncology-focused company Tesaro.
When the acquisition was announced, investors flagged their concern over the entrance into a particularly competitive area of the drugs market, with shares in GSK immediately sliding 7%.
GSK chief executive Emma Walmsley is likely to see the positive testing of Zejula as a vindication of the acquisition.
Zejula is a PARP inhibitor drug - a promising type of cancer drug which works by blocking enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells.
Investors have previously criticised GSK because the drug has lagged behind AstraZeneca-backed rival Lynparza, which has significantly higher sales.
GSK now appears more optimistic about the drug, after saying that it has now "met its endpoint of a statistically significant improvement in progression free survival for women".
Dr Hal Barron, chief scientific officer and president of research and development at GSK, said: "Almost 300,000 women around the world are diagnosed with ovarian cancer every year, yet only about 15% of patients are currently eligible to receive PARP inhibitors as their initial therapy.
"These exciting data demonstrate that Zejula has the potential to significantly benefit even more women with this devastating cancer."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here